Impact Factor 4.400

The 1st most cited open-access journal in Pharmacology & Pharmacy

Correction ARTICLE

Front. Pharmacol., 28 November 2017 | https://doi.org/10.3389/fphar.2017.00890

Corrigendum: Novel Peripherally Restricted Cannabinoid 1 Receptor Selective Antagonist TXX-522 with Prominent Weight-Loss Efficacy in Diet Induced Obese Mice

Wei Chen1,2, Fengchun Shui1,2, Cheng Liu3, Xinbo Zhou1,2, Wei Li1,2, Zhibing Zheng1,2, Wei Fu3 and Lili Wang1,2*
  • 1Beijing Institute of Pharmacology and Toxicology, Beijing, China
  • 2State Key Laboratory of Toxicology and Medical Countermeasures, Beijing, China
  • 3Department of Medicinal Chemistry, School of Pharmacy, Fudan University, Shanghai, China

A corrigendum on
Novel Peripherally Restricted Cannabinoid 1 Receptor Selective Antagonist TXX-522 with Prominent Weight-Loss Efficacy in Diet Induced Obese Mice

by Xie, X., Chen, W., Zhang, N., Yuan, M., Xu, C., Zheng, Z., et al. (2017). Front. Pharmacol. 8:707. doi: 10.3389/fphar.2017.00707

There is an error in the Funding statement. The correct number for the Major Program of the Ministry of Science and Technology of China is 2012ZX09301-001, 2012ZX09301-003.

In the original article, we neglected to include the funder the National Natural Science Foundation of China, 81430090 to LW.

The authors apologize for these errors and state that this does not change the scientific conclusions of the article in any way.

Conflict of Interest Statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Keywords: CB1R antagonist, obesity, periphery, blood–brain-barrier

Citation: Chen W, Shui F, Liu C, Zhou X, Li W, Zheng Z, Fu W and Wang L (2017) Corrigendum: Novel Peripherally Restricted Cannabinoid 1 Receptor Selective Antagonist TXX-522 with Prominent Weight-Loss Efficacy in Diet Induced Obese Mice. Front. Pharmacol. 8:890. doi: 10.3389/fphar.2017.00890

Received: 08 November 2017; Accepted: 20 November 2017;
Published: 28 November 2017.

Edited and reviewed by: Ming Wang, Phanes Therapeutics, United States

Copyright © 2017 Chen, Shui, Liu, Zhou, Li, Zheng, Fu and Wang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

*Correspondence: Lili Wang, wangll63@126.com